[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

BridgeBio Pharma CEO and director Kumar Neil reported the sale of common stock on August 7–8, 2025. The Form 4 discloses total dispositions of 217,404 shares, and notes the transactions were effected pursuant to a Rule 10b5-1 sales plan adopted March 31, 2025.

Footnotes disclose weighted average sale price ranges of approximately $44.31–$47.20 per share across the transactions. The filing lists indirect beneficial ownership following the reported transactions, including holdings of 4,718,447 and 915,686 shares via two trusts, and is signed by an attorney-in-fact on August 11, 2025.

Insights

Corporate Governance Expert

TL;DR: Sales were executed under a pre-established 10b5-1 plan, providing procedural compliance and disclosure.

The Form 4 documents 217,404 shares disposed by the reporting person on August 7–8, 2025, with the filer identified as both CEO and a director. Footnote 1 confirms the trades were made pursuant to a Rule 10b5-1 plan adopted March 31, 2025, which typically provides an affirmative defense against insider trading claims when properly structured. The form also discloses indirect holdings via two trusts and includes weighted average price ranges for the transactions, enhancing transparency. From a governance perspective, the filing shows regulatory compliance and clear disclosure of beneficial ownership following the trades.

Securities Analyst

TL;DR: CEO sold 217,404 BBIO shares at roughly $44–$47; market interpretation may be cautious despite the 10b5-1 plan.

The report records multiple sales on August 7 and 8, 2025, aggregating to 217,404 shares disposed, with weighted average sale price ranges disclosed in footnotes from about $44.31 up to $47.20 per share. Although the transactions were executed under a documented 10b5-1 plan, sizable insider dispositions by a CEO can attract investor attention and be interpreted in different ways. The filing includes the indirect beneficial ownership figures for trusts, which remain sizable. For investors, the key factual elements are the volume sold, the price ranges, and that the sales were preplanned and disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2025		S(1)		6,784	D	$45.0927(2)	4,751,663	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	08/07/2025		S(1)		13,216	D	$45.638(3)	4,738,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	08/08/2025		S(1)		11,795	D	$45.8806(4)	4,726,652	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	08/08/2025		S(1)		8,205	D	$46.7096(5)	4,718,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	08/07/2025		S(1)		6,784	D	$45.0927(2)	948,902	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	08/07/2025		S(1)		13,216	D	$45.638(3)	935,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	08/08/2025		S(1)		11,795	D	$45.8806(4)	923,891	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	08/08/2025		S(1)		8,205	D	$46.7096(5)	915,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Common Stock								217,404	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $44.31 to $45.305 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. Represents the weighted average sale price of the shares sold from $45.31 to $46.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

4. Represents the weighted average sale price of the shares sold from $45.49 to $46.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. Represents the weighted average sale price of the shares sold from $46.49 to $47.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

	/s/ Will Solis, Attorney-in-Fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.